Neumora Therapeutics, Inc. (NMRA) Q1 2025 Earnings
NMRA·Reported May 12, 2025·After market close
Diluted EPS came in at $-0.42 (-23.5% YoY), missed the $-0.40 consensus by $0.02.
Diluted EPS
$-0.42missed by $0.02
Consensus: $-0.40
Financial Snapshot
Trailing eight quarters through Q1 2025
Q1 2025 Earnings FAQ
Common questions about Neumora Therapeutics, Inc.'s Q1 2025 earnings report.
Neumora Therapeutics, Inc. (NMRA) reported Q1 2025 earnings on May 12, 2025 after market close.
Neumora Therapeutics, Inc. reported diluted EPS of $-0.42 for Q1 2025.
EPS missed the consensus estimate of $-0.40 by $0.02.
Compared to the same quarter a year prior, diluted EPS declined 23.5% from $-0.34.
You can read the 10-Q periodic report (0000950170-25-069311) directly on SEC EDGAR. The filing index links above go to sec.gov.